Biotechnology & Medical Research

Advaxis Inc completes $17 mln financing

Advaxis Inc:Executed definitive securities purchase agreements with two institutional investors for gross proceeds of about $16.7 mln in registered direct offering of about 3.9 mln shares at price of $4.25 per share.Adage Capital Management, L.P. (Adage) was lead investor in this financing, with...

3:34pm EST

FDA accepts IND application for Radius Health's investigational drug RAD1901 being developed for potential use in Metastatic Breast Cancer

Radius Health, Inc:Says that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for its investigational drug RAD1901, a tissue-selective estrogen receptor degrader (SERD) being developed for potential use in metastatic breast cancer.Says Phase 1...

10:07am EST

Amarantus BioScience Holdings, Inc submits orphan drug designation application to US FDA for treatment of Retinal Artery occlusion with product candidate MANF

Amarantus BioScience Holdings, Inc:Applies to the U.S. Food & Drug Administration (FDA) for Orphan Drug Designation for its investigational drug MANF (mesencephalic-astrocyte-derived neurotrophic factor) as a treatment for retinal artery occlusion (RAO).RAO is a blockage of the blood supply to the...

7:35am EST

Carna Biosciences Inc expects extraordinary loss for Q4 2014 and issues consolidated full-year outlook for FY 2014

Carna Biosciences Inc:Expects to record 208,780,000 yen impairment loss, as well as 28,185,000 yen impairment loss on fixed assets of subsidiary as extraordinary loss for the fourth quarter of the fiscal year ending Dec. 2014.Says the consolidated full-year outlook for revenue at 610 million yen for...

1:30am EST

Celltrion, Inc. declares annual stock dividend for 2014

Celltrion, Inc:To distribute an annual stock dividend of 0.05 new share for each existing share for 2014, to its shareholders of record on Dec. 31.Total distribution amount of 5,105,283 new shares.

Thursday, 18 Dec 2014 11:25pm EST

Progen Pharmaceuticals Limited announces successfully completes third patient Cohort

Progen Pharmaceuticals Limited:Says that it has completed assessment of the third patient cohort in its PG545 Phase 1 clinical trial.Progen together with an independent medical monitor and the co-ordinating investigators have reviewed the safety data from this cohort and have agreed to progress to...

Thursday, 18 Dec 2014 08:00pm EST

Newron Pharmaceuticals says CHMP recommends approval of Xadagotm (Safinamide) to treat Parkinson disease in the EU

Newron Pharmaceuticals SpA:Says CHMP recommends approval of Xadagotm (Safinamide) to treat Parkinson disease in the EU.

Thursday, 18 Dec 2014 07:00pm EST

Juno Therapeutics, Inc announces pricing of Initial Public Offering

Juno Therapeutics, Inc:Announces pricing of its initial public offering of 11,022,917 shares of common stock at a price to the public of $24.00 per share.Says in addition, Juno Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,653,437 shares of common stock...

Thursday, 18 Dec 2014 06:14pm EST

Aldeyra Therapeutics submits FDA IND filing for Noninfectious Anterior Uveitis

Aldeyra Therapeutics Inc:Announces that an Investigational New Drug application (IND) to conduct Phase 2 clinical testing of NS2.Says for treatment of noninfectious anterior uveitis, was submitted to United States Food and Drug Administration (FDA) on Dec. 16.

Thursday, 18 Dec 2014 08:30am EST

Bellicum Pharmaceuticals Inc prices initial public offering of 7,350,000 shares of common stock

Bellicum Pharmaceuticals Inc:Announced the pricing of its initial public offering of 7,350,000 shares of its common stock, an increase of 1,100,000 shares from the number of shares originally offered, at a public offering price of $19.00 per share.Says all of the shares of common stock are being...

Thursday, 18 Dec 2014 07:00am EST

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.

Analyst Research

Report Title Price
Provider: Thomson Reuters StreetEvents
$75.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.